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Abstract
It has been reported that feeding mice resveratrol activates AMPK and SIRT1 in skeletal muscle leading to deacetylation and
activation of PGC-1a, increased mitochondrial biogenesis, and improved running endurance. This study was done to further
evaluate the effects of resveratrol, SIRT1, and PGC-1a deacetylation on mitochondrial biogenesis in muscle. Feeding rats or
mice a diet containing 4 g resveratrol/kg diet had no effect on mitochondrial protein levels in muscle. High concentrations
of resveratrol lowered ATP concentration and activated AMPK in C2C12 myotubes, resulting in an increase in mitochondrial
proteins. Knockdown of SIRT1, or suppression of SIRT1 activity with a dominant-negative (DN) SIRT1 construct, increased
PGC-1a acetylation, PGC-1a coactivator activity, and mitochondrial proteins in C2C12 cells. Expression of a DN SIRT1 in rat
triceps muscle also induced an increase in mitochondrial proteins. Overexpression of SIRT1 decreased PGC-1a acetylation,
PGC-1a coactivator activity, and mitochondrial proteins in C2C12 myotubes. Overexpression of SIRT1 also resulted in a
decrease in mitochondrial proteins in rat triceps muscle. We conclude that, contrary to some previous reports, the
mechanism by which SIRT1 regulates mitochondrial biogenesis is by inhibiting PGC-1a coactivator activity, resulting in a
decrease in mitochondria. We also conclude that feeding rodents resveratrol has no effect on mitochondrial biogenesis in
muscle.
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Introduction
Resveratrol has been reported to have a number of remarkable
effects in mice. These include protection against high-fat-diet-
induced obesity and insulin resistance [1–3], marked improve-
ments in running endurance and maximal oxygen uptake capacity
(VO2max) [3], increased muscle strength [3], improved motor
coordination [1–3], and antiaging effects [1,2]. Subsequent studies
have shown that resveratrol does not have antiaging effects in
mice, as evidenced by no increases in average or maximum
longevity [4,5]. The protection against obesity and insulin
resistance was attributed to an increase in, and uncoupling of,
mitochondria in brown fat, and the increase in running endurance
and VO2max were attributed to an increase in muscle mitochon-
dria [3]. The increase in mitochondria induced by resveratrol was
explained by activation of the protein deacetylase SIRT1, resulting
in deacetylation and activation of the transcription coactivator
PGC-1a [3]. PGC-1a regulates mitochondrial biogenesis [6]. The
pharmaceutical agent SRT1720 has also been reported to activate
SIRT1, resulting in PGC-1a activation, and an increase in
enzymes of the mitochondrial fatty acid oxidation pathway in
muscle and improved running performance, muscle strength, and
coordination [7]. However, Pacholec et al. [8] have reported that
SRT1720 does not activate SIRT1, and that it does not induce an
increase in mitochondrial enzymes in mice. Based on studies on
yeast and in vitro, it was initially thought that resveratrol directly
activates SIRT1 [9]. However, Kaeberlein et al. [10] showed that,
although resveratrol binds and deacetylates peptide substrates that
contain a Fluor de Lys, it does not bind or deacetylate acetylated
peptides lacking the flurophore. They also found that resveratrol
has no effect on SIRT2 activity in yeast. Similarly, Bora et al. [11]
found that resveratrol activation of SIRT1 was completely
dependent on the presence of a covalently attached flurophore.
Evidence that resveratrol can activate AMP activated protein
kinase (AMPK) [12–14] led to further studies that indicated that
the activation of SIRT1 by resveratrol is indirect, and is mediated
by activation of AMPK [15]. The mechanism by which AMPK is
thought to activate SIRT1 is by increasing NAD concentration
[15].
We have a long-standing interest in the adaptive responses to
endurance exercise, such as running and swimming, which include
an increase in muscle mitochondria [16,17]. Endurance exercise
training also results in increases in endurance and in maximal
oxygen uptake capacity. Endurance exercise does not, by itself,
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result in increases in either muscle strength, which occurs in
response to heavy resistance exercise, or improved motor
coordination, which occurs in response to activities that require
various motor skills. A sedentary lifestyle greatly increases the risk
of developing obesity, insulin resistance, type 2 diabetes, athero-
sclerosis, and frailty [18]. Therefore, in addition to being necessary
for successful competition in sports, regular exercise is necessary
for maintenance of health and functional capacity. Because it is
difficult to motivate people to exercise, an effective, nontoxic
exercise mimetic—that is, an ‘‘exercise pill’’—could have great
public health value. Therefore, the reports that, in addition to
protecting against obesity and insulin resistance, resveratrol
feeding mimics not only the adaptive response to endurance
exercise but also the adaptations to strength training and motor
skill exercise training were of great interest to us. The present study
was undertaken to further evaluate the adaptive response of
skeletal muscle mitochondria to resveratrol treatment.
Results
Studies on Rats and Mice
Feeding rats resveratrol in a chow diet containing 4 g resveratrol per
kg diet [3] for 8 wk had no effect on the expression of PGC-1a or on a
number of mitochondrial proteins in rat skeletal muscle as shown in
soleus muscle (Figure 1A). A similar lack of effect was found in the
gastrocenemius muscle. Feeding rats a high fat diet containing 4 g
resveratrol per kg diet also had no effect on the expression of a range of
mitochondrial enzyme proteins (Figure 1B). To rule out the possibility
that the lack of effect of resveratrol on the mitochondrial content of
skeletal muscle in rats was due to a species difference, we fed mice a
high fat diet containing 4 g resveratrol per kg/diet as in the study by
Lagouge et al. [3]. As in the rats, resveratrol feeding had no effect on
the expression of PGC-1a or a number of mitochondrial proteins in
skeletal muscle of mice (Figure 1C). To evaluate the possibility that the
lack of effect of resveratrol on mitochondrial biogenesis is due to an
inadequate increase in plasma resveratrol, we measured plasma
resveratrol concentration. Plasma resveratrol concentration at 9:00 am
in rats in the fed state averaged 1.5660.28 mM. This plasma
resveratrol concentration is higher than that reported by Lagouge et
al. [3] in their resveratrol fed mice, in which the highest concentration
attained was ,0.5 mM.
Studies on C2C12 Myotubes
Most of the information regarding the effects of resveratrol on, and
the role of SIRT1 in, the regulation of mitochondrial biogenesis has
come from studies on C2C12 myotubes or other cells in culture.
Because resveratrol feeding had no effect on mitochondrial biogenesis
in laboratory rodents, we evaluated the effect of resveratrol on
mitochondrial biogenesis in C2C12 myotubes. The concentration of
resveratrol that was routinely used in studies on C2C12 myotubes by
Auwerx’s group was 50 mM [3,15],,100-fold higher than the highest
plasma resveratrol level in their resveratrol fed mice [3]. In our initial
experiments we found that 50 mM resveratrol is toxic, with a high
proportion of the C2C12 myotubes appearing to be dead or dying after
24 h of exposure to 50 mM resveratrol. That this concentration of
resveratrol is cytotoxic was born out by measurements of cytotoxicity
(Figure 2A) and of ATP concentration, which was markedly reduced
(Figure 2B). Similarly, Zang et al. [13] have reported that exposure of
Hep-G2 cells to 50 mM resveratrol for 60 min resulted in an 80%
reduction in ATP concentration. The decrease in ATP concentration
in cells exposed to a high concentration of resveratrol is mediated by
toxic effects onmitochondria, with inhibition of ATP synthase [19] and
NADH: ubiquinone oxidoreductase [20]. Numerous studies have
shown that concentrations of resveratrol in the 30 to 100 mM range kill
a variety of malignant cells [21]. These studies were uncontrolled, and
it was assumed that resveratrol specifically kills cancer cells. However,
the present finding and that of Zang et al. [13] show that resveratrol at
the high concentrations used is also lethal for nonmalignant cells.
Effect of PGC-1a Overexpression
In the study in which 50 mM resveratrol increased mitochon-
drial biogenesis in C2C12 myotubes [3], the investigators used cells
that overexpressed PGC-1a. We have observed that myotubes in
which PGC-1a is overexpressed have increased resistance to the
effect of puromycin (DH Han and JO Holloszy, unpublished
findings), suggesting the possibility that overexpression of PGC-1a
results in a nonspecific increase in resistance to toxins. We,
therefore, evaluated the effect of 50 mM resveratrol in C2C12 cells
in which PGC-1a was overexpressed by infection with a virus
expressing PGC-1a. As shown in Figure 2C, the toxic effect of
24 h exposure to 50 mM resveratrol on cell viability was markedly
reduced. However, there was still a significant reduction in ATP
concentration (Figure 2D). Treatment with 50 mM resveratrol for
24 h resulted in an increase in mitochondrial biogenesis in the
myotubes in which PGC-1a was overexpressed, as evidenced by
increases in the expression of a number of mitochondrial proteins
(Figure 3A). All of our subsequent experiments in which 50 mM
resveratrol was used were performed on C2C12 myotubes in which
PGC-1a was overexpressed.
Effect of 20 mM Resveratrol in the Absence of PGC-1a
Overexpression
To evaluate the effect of resveratrol in the absence of PGC-1a
overexpression, we tried to identify a resveratrol concentration
that induces an increase in mitochondrial proteins in wild type
C2C12 cells. Resveratrol concentrations in the 1 mM to 10 mM
Author Summary
Studies on cultured muscle cells have shown that
treatment with resveratrol, a chemical famously found in
the skin of red grapes, stimulates the manufacture of new
mitochondria. This has been attributed to the activation of
the deacetylase SIRT1 either directly by resveratrol or
indirectly via the activation of AMP-activated protein
kinase (AMPK). SIRT1 is then thought to deacetylate and
activate the transcriptional coactivator PGC-1a, which in
turn stimulates mitochondrial biogenesis. It has also been
reported that feeding resveratrol to mice increases muscle
mitochondria and results in improved running endurance.
Here we further analyze the adaptive response of muscle
mitochondria to resveratrol treatment to see if it mimics
the response to endurance exercise. We find that feeding
rats or mice large amounts of resveratrol did not increase
muscle mitochondria. In these rodents, the bioavailability
of oral resveratrol is low, and the resulting plasma level of
resveratrol is far below the concentration required to
activate AMPK. Contrary to previous reports we find that
deacetylation by SIRT1 decreases PGC-1a activity and
results in a decrease in mitochondria; moreover we show
that the increase in mitochondria induced in cultured
muscle cells by a high resveratrol concentration is due to
the toxic activation of AMPK and, in turn, PGC-1a.
However, this effect requires resveratrol concentrations
that are very much higher than those attained by oral
administration, and we conclude that oral resveratrol has
no effect on mitochondrial biogenesis in skeletal muscle.
SIRT1 Inhibits PGC-1 and Mitochondrial Biogenesis
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range did not result in a decrease in ATP concentration
(Figure 2B). Although exposure to 20 mM resveratrol for 24 h is
less toxic than exposure to 50 mM, it results in a decrease in cell
viability (Figure 2A) and a ,50% decrease in ATP concentration
(Figure 2B). Six hours of treatment with 20 mM resveratrol
resulted in a smaller decrease in ATP (,20%), and wild-type
C2C12 cells treated with 20 mM resveratrol for 6 h followed by an
18 h recovery period showed no evidence of toxicity. ‘‘Training’’
the wild-type C2C12 cells by exposing them to 20 mM resveratrol
for 6 h per day for 3 d resulted in increases in PGC-1a and a
number of mitochondrial proteins (Figure 3B), while the same
treatment with 1 mM, 5 mM, or 10 mM resveratrol had no effect
(Figure S1).
AMPK Is Necessary for the Resveratrol-Induced Increase
in Mitochondrial Biogenesis
As shown in Figure 4A, treatment with 20 mM resveratrol
resulted in increased phosphorylation of AMPK and acetyl-CoA
carboxylase (ACC) in C2C12 myotubes. As a first step in evaluating
the relative roles of AMPK and SIRT1 in the resveratrol-induced
Figure 1. Feeding rodents resveratrol does not induce mitochondrial biogenesis in skeletal muscle. (A) Feeding rats a chow diet
containing 4 g resveratrol (RSV) per kg diet for 8 wk had no effect on expression of PGC-1a or mitochondrial enzyme proteins in soleus muscle. (B)
Feeding rats a high fat diet containing 4 g RSV per kg diet for 8 wk had no effect on expression of PGC-1a or mitochondrial enzyme proteins in
triceps muscle. (C) Feeding mice a high fat diet containing 4 g resveratrol per kg diet had no effect on expression of PGC-1a or mitochondrial
proteins in triceps muscle. Values are means 6 SE for 6–8 muscles per group.
doi:10.1371/journal.pbio.1001603.g001
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increase in mitochondrial biogenesis, we infected C2C12 myotubes
with an adenovirus encoding a dominant-negative AMPK gene
construct. That the DN AMPK was effective in blocking AMPK
activity is demonstrated by prevention of increases in AMPK and
ACC phosphorylation in response to resveratrol treatment
(Figure 4B). Blocking AMPK activity prevented induction of an
increase in mitochondrial proteins by resveratrol (Figure 4C),
showing that AMPK activation is necessary for stimulation of
mitochondrial biogenesis by resveratrol.
Inhibition of SIRT1 Does Not Prevent the Resveratrol-
Induced Increase in Mitochondrial Biogenesis
Ja¨ger et al. [22] have shown that AMPK directly phosphorylates
and activates PGC-1a. Canto et al. [15] have interpreted their
data to indicate that phosphorylation of PGC-1a by AMPK
constitutes a priming event for subsequent deacetylation by
SIRT1, and that deacetylation of PGC-1a is a key mechanism
by which AMPK triggers PGC-1a activity. To further evaluate the
relative roles of SIRT1 and AMPK in the resveratrol-induced
increase in mitochondria, we used nicotinamide to inhibit SIRT1
[23]. That 10 mM nicotinamide decreases SIRT1 activity in
C2C12 myotubes is evidenced by the finding of increases in the
acetylation of p53, which is a SIRT1 substrate [24] (Figure 5A)
and of PGC-1a (Figure 5C). Nicotinamide also prevented p53
deacetylation in response to 50 mM resveratrol (Figure 5A).
However, we were surprised to find that nicotinamide did not
prevent the resveratrol-induced increase in mitochondrial proteins
(Figure 5B). Treatment of C2C12 myotubes with 10 mM
nicotinamide had no effect on ATP concentration (nicotinamide
5.360.l3 mmol/g protein, Control 5.760.18; n=6 per group).
Effects of Suppressing or Increasing SIRT1 Activity
We further evaluated the role of SIRT1 in mitochondrial
biogenesis by suppression of SIRT1 activity by adenovirus-
mediated expression of a dominant-negative (DN) SIRT1
H355A [23], and knockdown of SIRT1 with a shRNA, in
C2C12 myotubes. SIRT1 H355A suppressed SIRT1 activity as
evidenced by an increase in PGC-1 acetylation and inhibition of
resveratrol-induced PGC-1a deacetylation (Figure 5C). Both the
DN SIRT1 and the SIRT1 shRNA resulted in increased PGC-1a
coactivator activity, measured in C2C12 myotubes co-transfected
Figure 2. 50 mM resveratrol is toxic to C2C12 myotubes. (A) Exposure to 50 mM resveratrol (RSV) for 24 h is toxic to C2C12 myotubes resulting in
a decrease in viable cells and (B) a decrease in ATP content. Values are means 6 SE for 4–6 experiments. (C) PGC-1a overexpression in C2C12
myotubes protects against the toxic effect of 24 h exposure to 50 mM RSV on viability and (D) ATP content. Values are means 6 SE for six
experiments. *p,0.05 versus basal.
doi:10.1371/journal.pbio.1001603.g002
SIRT1 Inhibits PGC-1 and Mitochondrial Biogenesis
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with a PGC-1a–GAL4 fusion construct and a luciferase reporter
[25], and enhanced the resveratrol-induced increase in PGC-1a
activity (Figure 5D). Overexpression of wild-type SIRT1 resulted
in PGC-1a deacetylation (Figure 5C), reduced PGC-1a coacti-
vator activity, and prevented the increase in PGC-1a activity
induced by resveratrol (Figure 5D).
SIRT1 H355A expression in myotubes resulted in an increase
in mitochondrial enzyme proteins (Figure 6A). Expression of
SIRT1 H355A in rat triceps muscle by electroporation also
resulted in an increase in mitochondrial enzyme proteins
(Figure 6B). Furthermore, knockdown of SIRT1 by transfection
of C2C12 myotubes with a SIRT1 shRNA brought about an
increase in mitochondrial proteins, providing further evidence that
acetylation activates PGC-1a (Figure 6C). Expression of DN
SIRT1 H355A in C2C12 myotubes had no effect on ATP
concentrations (Control 5.760.18, DN SIRT1 H355A 6.060.3;
n=6 per group). To further evaluate the effect of SIRT1 on
mitochondrial biogenesis, we determined the effect of overexpres-
sion of SIRT1 by adenovirus mediated infection of C2C12 cells,
and electroporation of rat triceps muscle, with a SIRT1 gene
construct. SIRT1 overexpression resulted in a decrease in
cytochrome c and inhibited the resveratrol-induced increase in
cytochrome c in C2C12 myotubes (Figure 6D). Overexpression of
SIRT1 in rat triceps muscle resulted in decreases in mitochondrial
enzyme proteins (Figure 6E).
Interestingly, the increase in PGC-1a coactivator activity
induced by acetylation does not result in an increase in PGC-1a
expression (Figure 6). This is in contrast to PGC-1a activation by
phosphorylation by AMPK and/or p38 MAPK, which is
associated with an increase in PGC-1a expression (Figure 3B)
[22,26–29]. A probable explanation for this difference is that
AMPK and p38 MAPK do not just activate PGC-1, but also
activate the transcription factors that induce increased PGC-1a
expression. P38 MAPK phosphorylates and activates ATF2, which
binds to a CREB binding site on the PGC-1a promoter, and
AMPK and p38 MAPK bring about activation of MEF2, which
binds to a MEF2 binding site on the PGC-1a promoter, resulting
in increased PGC-1a transcription [27,30–32].
Discussion
In the present study, resveratrol feeding had no effect on
mitochondrial biogenesis in skeletal muscle even though our
animals were fed a diet containing the same amount of resveratrol,
4 g/kg diet, as used by Lagouge et al. [3], and more than the dose,
0.4 g/kg diet, used by Bauer et al. [1]. In studies on the effects of
resveratrol on cells in culture, concentrations in the 30 mM to
100 mM range have routinely been used [3,12,14,15]. Based on
our findings on C2C12 myotubes, the concentration of resveratrol
required to induce an increase in mitochondrial biogenesis is
above 10 mM, and the data shown by Bauer et al. [1] suggest the
concentration of resveratrol needed to activate AMPK in CHO
cells is also above 10 mM. The plasma resveratrol concentration in
our rats was 1.5660.28 mM and the highest concentration in the
mice of Lagouge et al. [3] was ,0.5 mM. Thus, a likely
explanation for the failure of resveratrol feeding to induce
mitochondrial biogenesis in rats and mice in our study is its poor
bioavailability.
In our experiments on C2C12 cells, we confirmed the finding of
Lagouge et al. [3] that treatment of C2C12 cells with a high
concentration of resveratrol results in both PGC-1a activation,
evaluated using a PGC-1a–GAL4 construct together with a
luciferase reporter, and an increase in mitochondrial biogenesis.
The research groups of Auwerx and Puigserver have published a
Figure 3. High concentrations of resveratrol induce an increase
in mitochondrial proteins in C2C12 myotubes. (A) Treatment with
50 mM resveratrol (RSV) for 24 h resulted in an increase in mitochondrial
proteins in C2C12 myotubes in which PGC-1a was overexpressed by
infection with an adenovirus expressing PGC-1a (AdPGC-1a). Values are
means 6 SE for 7–8 experiments. (B) Treatment of wild-type C2C12
myotubes with 20 mM RSV for 6 h, followed by 18 h recovery, for 3 d
induced increases in PGC-1a and mitochondrial proteins. Values are
means 6 SE for 6–8 experiments. *RSV versus control, p,0.05.
doi:10.1371/journal.pbio.1001603.g003
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large number of studies, reporting that deacetylation activates and
acetylation deactivates PGC-1a [3,7,15,33–39]. Phosphorylation
of PGC-1a by AMPK results in PGC-1 activation and increased
mitochondrial biogenesis [22]. We found that high concentrations
of resveratrol activate AMPK in C2C12 cells by a toxic effect on
mitochondria that reduces ATP level, and that this is the
mechanism by which resveratrol activates PGC-1a. We also
found that the concomitant increase in SIRT1 activity, also
mediated by AMPK, results in a deacetylation of PGC-1a that
causes a blunting of the increase in PGC-1a activity induced by
AMPK. This is in contrast to the report by Canto et al. [15] that
activation of PGC-1a by AMPK is dependent on PGC-1a
deacetylation by SIRT1. In support of this conclusion, they
reported that inhibition of SIRT1 with nicotinamide or knock
down of SIRT1 markedly reduced PGC-1a activation and
attenuated the increase in mitochondrial proteins in response to
AMPK activation.
We confirmed that activation of AMPK results in SIRT1
activation, as evidenced by deacetylation of p53 and PGC-1a. We
also confirmed that suppression of AMPK activity blocks the
increase in mitochondrial proteins induced by resveratrol.
However, we were surprised to find that inhibiting SIRT1 with
nicotinamide did not prevent the resveratrol-induced increase in
mitochondrial proteins in C2C12 myotubes. Furthermore, an
increase in PGC-1a acetylation, mediated by suppression of
SIRT1 activity using a dominant-negative SIRT1 construct,
resulted in an increase in PGC-1a coactivator activity and
mitochondrial biogenesis. Knockdown of SIRT1 also increased
PGC-1a activity. Further evidence that PGC-1 is activated by
acetylation is provided by the findings that overexpression of wild-
type SIRT1, resulting in PGC-1 deacetylation, decreases mito-
chondrial proteins, blunts the resveratrol/AMPK-induced in-
crease in cytochrome c, and reduces PGC-1a coactivator activity.
An additional mechanism by which the inhibitory effect of SIRT1
on PGC-1a activity might be mediated is by deacetylation and
inactivation of the transacetylase p300 [40]. p300 is a transacet-
ylase that binds to and acetylates PGC-1a [41], and powerfully
enhances its coactivator activity [42]. Thus, inactivation of p300,
resulting in decreased PGC-1a acetylation, could result in a
reduction of PGC-1a activity.
Our findings that SIRT1 activation decreases PGC-1a
coactivator activity and that inhibition or knockdown of SIRT1
increases PGC-1a activity are in keeping with data reported by
Finkel’s group [41]. These investigators showed that SIRT1 binds
to and deacetylates PGC-1a, and that increasing SIRT1
expression in PC12 cells results in a ,25% reduction in O2
consumption, a ,45% decrease in cytochrome oxidase (COX)
subunit 2 expression, and a,50% decrease in activity of a GAL4–
PGC-1a fusion construct [41]. They also found that overexpres-
sion of the transacetylase p300, which activates PGC-1a [42],
dramatically increased PGC-1a acetylation [41]. Our findings also
Figure 4. Resveratrol activates AMPK. (A) Treatment of C2C12
myotubes with 20 mM resveratrol (RSV) for 3 h results in increased
phosphorylation of AMPK and acetyl CoA carboxylase (ACC). (B)
Blocking AMPK activity by expression of dominant-negative AMPK
(DN AMPK) in C2C12 myotubes prevents AMPK and ACC phosphoryla-
tion in response to RSV treatment. Nicotinamide had no effect on AMPK
or ACC phosphorylation. (C) Blocking AMPK activity (DN AMPK)
prevents induction of an increase in mitochondrial proteins by
resveratrol. In experiments in which C2C12 myotubes were treated with
50 mM resveratrol, PGC-1a was overexpressed in the myotubes (see
Figure 3 and text). Values are means 6 SE for 6–8 experiments. *RSV
versus other groups, p,0.05.
doi:10.1371/journal.pbio.1001603.g004
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confirm the report by Gurd et al. [43] that overexpression of
SIRT1 in rat skeletal muscle results in decreased expression of the
mitochondrial enzyme COXIV. Gurd et al. [43] also found an
inverse relationship between mitochondrial content and SIRT1
content in different types of skeletal muscle and heart muscle.
SIRT1 is induced by, and appears to play a key role in the
adaptive responses to, fasting, starvation, and calorie restriction
[44–47]. The Auwerx and Puigserver research groups have
interpreted their findings to indicate that SIRT1 leads to increased
mitochondrial biogenesis, which provides a molecular mechanism
that allows cells to survive and adapt to periods of nutrient
deprivation [35], that SIRT1 activation by SRT1720 mimics low
energy levels [7], and that ‘‘interdependent regulation of SIRT1
and AMPK provide a finely tuned amplifier mechanism for energy
homeostasis under low energy availability’’ [15]. A key component
of this concept is that mitochondrial adaptations induced by
increased SIRT1 activity are necessary for the switch from
carbohydrate to fat oxidation in response to fasting [7,35]. What
was actually reported is that treatment with resveratrol [3] or
SIRT1720 [7] and other interventions that activated SIRT1
[34,38] resulted in increases in basal oxygen consumption, heat
production/body temperature, and protection against weight gain
or reduced weight gain despite no decrease in food consumption.
This syndrome, which resembles hyperthyroidism, was attributed
by the authors to mitochondrial adaptations in brown adipose
tissue and is incompatible with the large increase in running
endurance reported in these mice [3,7,38].
Adaptive responses were selected for because they enhance an
organism’s chances of surviving environmental changes. Increases
in energy expenditure and substrate oxidation resulting in more
rapid depletion of energy stores, such as were reported to occur
with SIRT1 activation, would be seriously maladaptive responses
to fasting, starvation, or CR. Actually, it is well documented that
fasting and CR result in decreases in metabolic rate, as reflected in
lower resting oxygen consumption and a decrease in body
temperature [48–51]. With regard to the claim that an increase
in mitochondrial fatty acid oxidation enzymes is necessary for the
switch from carbohydrate to fatty acid oxidation in muscle [7,35],
no increase in mitochondria is needed. Skeletal muscle has a low
rate of energy utilization at rest and contains sufficient mitochon-
dria to make possible a many-fold, acute increase in fatty acid
oxidation in response to exercise that greatly exceeds the increase
in fat oxidation in muscle in response to fasting. Furthermore,
SIRT1-null mice are hypermetabolic, have elevated rates of fatty
acid utilization, and readily switch from carbohydrate to fat
oxidation in response to fasting [52].
In conclusion, our results show that resveratrol feeding does not
induce an increase in muscle mitochondria in rodents. This lack of
effect may be due to poor bioavailability, because the plasma levels
of resveratrol attained in response to feeding large amounts of
resveratrol are far below the concentration of resveratrol required
to activate AMPK. This seems fortunate, because the activation of
AMPK by resveratrol is mediated by a toxic effect that depletes
ATP in cells exposed to AMPK-activating concentrations of
resveratrol. Surprisingly, in light of the many studies reporting that
deacetylation of PGC-1a results in activation of PGC-1a’s
coactivator activity, we find that deacetylation decreases, and
PGC-1a acetylation increases, PGC-1a activity and mitochondrial
biogenesis. Our results indicate that the activation of PGC-1a by
resveratrol is mediated by AMPK, and that the activation of
SIRT1 by AMPK acts to reduce, rather than induce, this
activation.
Experimental Procedures
Ethics Statement
This research was approved by the Animal Studies Committee
of Washington University School of Medicine. Rats were lightly
anesthetized during muscle electroporation. Rats were anesthe-
tized with pentobarbital and, after muscles were harvested, were
killed by exsanguination while under anesthesia.
Materials
Antibodies against cytochrome oxidase subunit I (COXI),
cytochrome oxidase subunit IV (COX IV), Core II, Complex III
FeS, NADH ubiquinol oxidoreductase (NADH-UO), and succi-
nate ubiquinol oxidoreductase(SUO) ATP synthase alpha subunit
#45924 and lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA). Anti-cytochrome c antibody was obtained from
BD Biosciences (San Jose, CA). Antibodies against p53, acetyl-p53,
AMP-activated protein kinase (AMPK), phospho-AMPK, acetyl-
CoA carboxylase (ACC) and phospho-ACC were products of Cell
Signaling technology (Beverly, MA). An anti-SIRT1 antibody
#09844 was purchased from EMD Millipore. An anti-PGC-1a c-
terminal (777–797) antibody #516557 was purchased from EMD
Millipore (Billerica, MA); an antibody against acetylated lysine
#9441 was purchased from Cell Signaling (Beverly, MA).
Horseradish peroxidase (HRP)–conjugated donkey anti-rabbit
IgG and donkey anti-mouse IgG were purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA). Enhanced
chemiluminescence (ECL) reagents were obtained from Amer-
sham (Arlington Heights, IL). All other reagents were purchased
from Sigma (St. Louis, MO).
Resveratrol Feeding Studies
This research was approved by the Animal Studies Committee
of Washington University School of Medicine. Male Wistar rats
weighing ,95 g were purchased from Charles Rivers (Wilming-
ton, MD) and housed in individuals cages. The resveratrol used in
the study on rats was purchased from Stryka Botanicals
(Hillsborough, NJ). Control rats were fed Purina rodent chow,
and the resveratrol-fed rats were given the chow diet containing
Figure 5. Suppression of SIRT1 activity increases PGC-1a acetylation and coactivator activity. (A) Nicotinamide (Nic) decreases SIRT1
activity in C2C12 myotubes as evidenced by increased p53 acetylation and prevention of p53 deacetylation in response to resveratrol (RSV). *p,0.05
versus control; #p,0.05 versus RSV and RSV+Nic. (B) Inhibition of SIRT1 with nicotinamide (Nic) does not prevent the resveratrol (RSV)-induced
increase in mitochondrial proteins. *p,0.05 versus control. (C) Suppression of SIRT1 activity with nicotinamide or with dominant-negative SIRT1
H355A results in increased acetylation of PGC-1a. SIRT1 H355A reduces PGC-1a deacetylation in response to resveratrol (RSV) treatment, while
overexpression of wild-type (WT) SIRT1 results in PGC-1a deacetylation. Values are means6 SE for 6–8 experiments. *p,0.05 versus control; #p,0.05
versus other groups. (D) PGC-1a coactivator activity, measured in C2C12 myotubes co-transfected with a PGC-1a GAL4 fusion product and a luciferase
reporter, was increased by treatment with 20 mM resveratrol (RSV). Overexpression of wild-type (WT) SIRT1 resulted in reduced PGC-1a coactivator
activity. Suppression of SIRT1 activity with dominant-negative SIRT1 H355A or knockdown of SIRT1 with SIRT1 shRNA resulted in increases in PGC-1a
coactivator activity and potentiation of the effect of resveratrol on PGC-1a activity. In the experiments in which C2C12 myotubes were treated with
50 mM resveratrol, PGC-1a was overexpressed in the myotubes (see Figure 3 and text). Values are means 6 SE for 6–7 experiments. *p,0.05 versus
control; #p,0.05 versus basal.
doi:10.1371/journal.pbio.1001603.g005
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Figure 6. Reducing SIRT1 activity increases, and increasing SIRT1 expression decreases, mitochondrial enzymes in C2C12 myotubes
and rat skeletal muscle. (A) Suppression of SIRT1 activity with dominant-negative SIRT1 H355A in C2C12 myotubes increases mitochondrial
proteins. Values are means 6 SE for 6–10 experiments per group. p,0.5 versus control. (B) Suppression of SIRT1 activity by expression of dominant-
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4 g resveratrol per kg diet, for 8 wk. Male c57BL/6J mice were
purchased from Jackson Laboratory (Bar Harbor, ME), housed 6
per cage, and fed a high fat diet, 50% of calories from fat, or the
high fat diet containing 4 g resveratrol per kg diet [3] for 8 wk.
The resveratrol used in the study on mice was a kind gift from
DSM Nutritional Products (Basel, Switzerland). (The resveratrol
used in the study by Lagouge et al. was from Orchid, Chennai,
India.)
Muscle Harvesting
Rats or mice were anesthetized with sodium pentobarbital
5 mg/100 g body weight. Muscles were dissected out, clamp-
frozen, and kept at 280uC until used for assays.
C2C12 Myotube Viability Evaluation
ATP concentration was measured using a luminescence ATP
detection assay (ATPlite, Perkin Elmer, Waltham, MA); LDH
activity, as an indicator of cytotoxicity, was measured using an
LDH-Cytotoxicity Assay Kit (BioVision, Mountain View, CA),
according to the manufacturer’s instructions.
Constructs
For expression in skeletal muscle via electroporation, wild-type
SIRT1 and dominant-negative SIRT-1 H355A constructs were
purchased from Addgene (Cambridge, MA) and inserted into
pCDNA3.1 (Invitrogen, Carlsbad, CA). For expression in C2C12
myoblasts by transfection, a gal-4-DBD-PGC-1a plasmid was
purchased from Addgene (Cambridge, MA) [53], a 96gal-4–
dependent reporter plasmid was purchased from Promega
(Madison, WS), and a LacZ control plasmid was purchased from
Invitrogen (Carlsbad, CA). For expression by adenoviral infection
in C2C12 myotubes, the adenoviral constructs of pAd-Track Flag-
PGC-1a [36], pAd-Track Flag-SIRT1 [23], and pAd-Track Flag
dominant-negative SIRT1 H355A [23] were purchased from
Addgene (Cambridge, MA). Dominant-negative Myc-AMPKa 2
DNA [54] was PCR cloned and ligated into pAd-Track plasmid.
Mouse SIRT1 shRNA (59-GCCCTGTAAAGCTTTCAGAA-39)
and scrambled control (59-GATGAAGTCGACCTCCTCAT-39)
sequences were cloned into pRNAT-H1.1/adeno (Genescript,
Piscataway, NJ). Recombinant adenoviruses were generated
employing a system described by He et al. [55].
Muscle Electroporation
Transfection of DNA into rat skeletal muscle was accomplished by
using an electric pulse-mediated gene transfer technique [56]. Male
Wistar rats weighing ,60 g were anesthetized with isoflurane gas. A
triceps muscle was injected with 100 mg of plasmid DNA containing
either empty vector, pcDNA3.1 SIRT1 WT, or pcDNA3.1 Sirt1
H355A in 100 ml saline, using a 27 gauge needle, at a rate of 0.04 ml/
min. After injection, an electric field was applied to the triceps muscle
using a S88 square-pulse stimulator (Grass) with a 533 model two-
needle array (BTX). The electric field application consisted of 8 pulses
of 100 ms duration, at a frequency of 1 Hz and amplitude of 100 volts,
that were applied perpendicular to themuscles’ long axis.Muscles were
harvested 14 d after electroporation.
Cell Culture, Treatments, and Adenoviral Infections
C2C12 mouse myoblasts were grown in DMEM (4.5 g glucose/
L, Invitrogen) containing 10% fetal bovine serum, 100 mU/ml
penicillin, and 100 mU/ml streptomycin. Differentiation was
initiated by switching to medium containing 2% heat inactivated
horse serum when the myoblasts were 90% confluent. After 48 h
of differentiation, batches of myotubes were infected with
adenoviruses expressing (a) Flag-PGC-1a, (b) dominant-negative
Myc-AMPKa 2, (c) dominant-negative Flag-SIRT1 H355A, (d)
Flag-SIRT1, and (e) SIRT1 shRNA. At 96 h after differentiation,
batches of C2C12 myobutes were treated with 20 mM or 50 mM
resveratrol or vehicle for the time periods given in the figures, or
with 10 mM nicotinamide or vehicle for 24 h.
Western Blotting
Homogenates were prepared and Western blotting was
performed as described previously [57] using the antibodies
described previously [57,58].
PGC-1a Activity Assay
To evaluate the effect of SIRT1 on PGC-1a transcription
coactivator activity, C2C12 myoblasts were co-transfected with a
gal-4-DBD PGC-1a plasmid, and a 96gal-4-dependent reporter
plasmid, or with a LacZ control plasmid, and with either wild-type
SIRT1, dominant-negative SIRT1 H355A, or SIRT1 shRNA-
plasmids using lipofectamine 2000. After overnight transfection
the culture medium was changed to DMEM containing 10% FBS.
Thirty-six hours later, some of the cells were treated with 20 mM
resveratrol for 6 h and harvested after a 6 h recovery period. Dual
luciferase assays were performed using a kit (Invitrogen) according
to the manufacturer’s instructions.
PGC-1a Acetylation
Flag-PGC-1a was expressed in C2C12 myotubes by adenoviral
infection. To evaluate the effect of SIRT1 on PGC-1a acetylation,
the myotubes were co-infected with wild-type SIRT1 or SIRT1
H355A. Forty-eight hours after infection, myotubes were treated
with 50 mM resveratrol or vehicle for 18 h. Wild-type C2C12
myotubes were treated with 10 mM nicotinamide for 24 h. The
myotubes were then harvested, and cell extracts containing 200 mg
of protein were rotated with anti-Flag antibody at 4uC overnight.
The following morning, agarose G beads were added and the
samples were rotated at room temperature for 2 h. The agarose
beads were washed 4 times with PBS and protein was eluted from
the beads with 56SDS buffer, which was boiled for 5 min. PGC-
1a was measured with an anti-PGC-1a antibody, and levels of
PGC-1a acetylation were then assessed with an anti-acetyl lysine
antibody (#9441 Cell Signaling Technology).
Statistical Analysis
Results are expressed as means 6 SE. The significance of
differences between two groups was determined using Student’s t
test. For multiple comparisons, significance was determined by
one-way analysis of variance followed by post hoc comparison
using Tukey significant difference method.
negative SIRT1 H355A in rat triceps muscle by electroporation resulted in increases in mitochondrial proteins. Values are means6 SE for 5–7 muscles
per group. *p,0.05 versus control. (C) Knockdown of SIRT1 with a SIRT1 shRNA in C2C12 myotubes resulted in increases in mitochondrial proteins.
Values are means 6 SE for 6–8 experiments per group. *p,0.05 versus control. (D) Overexpression of wild-type (WT) SIRT1 in C2C12 myotubes
resulted in decreased cytochrome c protein expression and inhibited the resveratrol (RSV)-induced increase in cytochrome c. Values are means 6 SE
for 6 experiments. *p,0.05 versus control. #p,0.05 versus other groups. (E) Overexpression of wild-type (WT) SIRT1 in rat triceps muscle by
electroporation resulted in decreased expression of mitochondrial proteins. Values are means6 SE for 7–8 muscles per group. *p,0.05 versus empty
vector.
doi:10.1371/journal.pbio.1001603.g006
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Supporting Information
Figure S1 Treatment of C2C12 myotubes with 1.0 mM, 5 mM,
or 10 mM of resveratrol for 24 h had no effect on expression of
PGC-1a or mitochondrial enzyme proteins.
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